Insider Selling: Hims & Hers Health (NYSE:HIMS) CEO Sells 128,127 Shares of Stock

Key Points

• Hims & Hers Health CEO Andrew Dudum sold 128,127 shares of stock at an average price of $45.06, amounting to over $5.7 million, which reduced his ownership by 58.87%.
• In addition to the recent sale, Dudum has made multiple stock transactions recently, including selling over 660,000 shares for a total of approximately $33.4 million earlier in August.
• The company's most recent earnings report showed a slight miss on EPS expectations, with a report of $0.17 compared to the consensus $0.18, and revenues of $544.83 million, which was below analysts' estimates of $550.06 million.

Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report) CEO Andrew Dudum sold 128,127 shares of the stock in a transaction on Monday, August 18th. The shares were sold at an average price of $45.06, for a total value of $5,773,402.62. Following the completion of the sale, the chief executive officer directly owned 89,521 shares of the company's stock, valued at $4,033,816.26. The trade was a 58.87% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

Andrew Dudum also recently made the following trade(s):

• On Thursday, August 7th, Andrew Dudum sold 660,000 shares of Hims & Hers Health stock. The shares were sold at an average price of $50.58, for a total value of $33,382,800.00.
• On Monday, July 21st, Andrew Dudum sold 125,335 shares of Hims & Hers Health stock. The shares were sold at an average price of $49.54, for a total value of $6,209,095.90.
• On Wednesday, July 16th, Andrew Dudum sold 47,534 shares of Hims & Hers Health stock. The shares were sold at an average price of $50.25, for a total value of $2,388,583.50.
• On Wednesday, July 16th, Andrew Dudum sold 2,792 shares of Hims & Hers Health stock. The shares were sold at an average price of $50.58, for a total value of $141,219.36.
• On Tuesday, June 17th, Andrew Dudum sold 65,110 shares of Hims & Hers Health stock. The shares were sold at an average price of $59.22, for a total value of $3,855,814.20.
• On Monday, June 16th, Andrew Dudum sold 47,534 shares of Hims & Hers Health stock. The shares were sold at an average price of $56.51, for a total value of $2,686,146.34.
• On Monday, June 16th, Andrew Dudum sold 128,127 shares of Hims & Hers Health stock. The shares were sold at an average price of $56.76, for a total value of $7,272,488.52.

Hims & Hers Health Trading Up 3.1%

Shares of Hims & Hers Health stock opened at $43.4750 on Thursday. Hims & Hers Health, Inc. has a 1 year low of $13.47 and a 1 year high of $72.98. The firm has a market cap of $9.83 billion, a PE ratio of 54.34, a P/E/G ratio of 2.85 and a beta of 2.08. The stock has a fifty day moving average price of $52.18 and a 200-day moving average price of $45.73. The company has a debt-to-equity ratio of 1.72, a current ratio of 4.98 and a quick ratio of 4.46.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last announced its earnings results on Monday, August 4th. The company reported $0.17 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.18 by ($0.01). Hims & Hers Health had a net margin of 9.63% and a return on equity of 26.26%. The business had revenue of $544.83 million for the quarter, compared to analysts' expectations of $550.06 million. During the same period in the prior year, the business earned $0.06 earnings per share. The company's revenue for the quarter was up 72.6% compared to the same quarter last year. Hims & Hers Health has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. Equities research analysts anticipate that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in HIMS. Envestnet Asset Management Inc. boosted its stake in Hims & Hers Health by 139.2% in the 4th quarter. Envestnet Asset Management Inc. now owns 78,686 shares of the company's stock worth $1,903,000 after purchasing an additional 45,791 shares during the period. Mariner LLC boosted its stake in Hims & Hers Health by 77.4% in the 4th quarter. Mariner LLC now owns 19,943 shares of the company's stock worth $482,000 after purchasing an additional 8,699 shares during the period. Guggenheim Capital LLC bought a new position in Hims & Hers Health in the 4th quarter worth about $274,000. NewEdge Advisors LLC boosted its stake in Hims & Hers Health by 83.4% in the 4th quarter. NewEdge Advisors LLC now owns 20,021 shares of the company's stock worth $484,000 after purchasing an additional 9,105 shares during the period. Finally, First Trust Advisors LP boosted its stake in Hims & Hers Health by 46.5% in the 4th quarter. First Trust Advisors LP now owns 355,103 shares of the company's stock worth $8,586,000 after purchasing an additional 112,772 shares during the period. Institutional investors own 63.52% of the company's stock.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on HIMS. Piper Sandler reissued a "neutral" rating and issued a $39.00 price objective (up previously from $35.00) on shares of Hims & Hers Health in a report on Tuesday, May 6th. Needham & Company LLC reissued a "hold" rating on shares of Hims & Hers Health in a report on Tuesday, August 5th. TD Cowen lowered Hims & Hers Health from a "buy" rating to a "hold" rating and decreased their price objective for the stock from $44.00 to $30.00 in a report on Tuesday, April 29th. Morgan Stanley reissued an "equal weight" rating and issued a $40.00 price objective on shares of Hims & Hers Health in a report on Wednesday, June 11th. Finally, Wall Street Zen lowered Hims & Hers Health from a "buy" rating to a "hold" rating in a report on Monday, July 28th. Two investment analysts have rated the stock with a Buy rating, seven have given a Hold rating and three have issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Reduce" and a consensus price target of $38.92.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.